EGFR and its ligand TGF-α and EGFR2 [4] were found to be overexpressed in many breast cancer cases and are correlated with meagre prognosis, resistance, or dearth of response to treatments with hormones [5–7]. Here, EGFR is linked to breast carcinoma.